T1	Participants 123 211	patients with common cancers involving bone receiving intravenous bisphosphonate therapy
T2	Participants 476 515	Enrolled in the study were 184 patients
T3	Participants 1370 1403	12% of eligible patients (16/138)
T4	Participants 1758 1773	Cancer patients
